Cynthia Louise Flowers Net Worth

The estimated Net Worth of Cynthia Louise Flowers is at least $295 Thousand dollars as of 12 March 2020. Cynthia Flowers owns over 31,000 units of Kadmon Inc stock worth over $294,500 and over the last 6 years Cynthia sold KDMN stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Cynthia Flowers KDMN stock SEC Form 4 insiders trading

Cynthia has made over 2 trades of the Kadmon Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Cynthia bought 31,000 units of KDMN stock worth $100,440 on 12 March 2020.

The largest trade Cynthia's ever made was buying 31,000 units of Kadmon Inc stock on 12 March 2020 worth over $100,440. On average, Cynthia trades about 1,706 units every 23 days since 2018. As of 12 March 2020 Cynthia still owns at least 31,000 units of Kadmon Inc stock.

You can see the complete history of Cynthia Flowers stock trades at the bottom of the page.

What's Cynthia Flowers's mailing address?

Cynthia's mailing address filed with the SEC is 700 PARK OFFICES DRIVE, SUITE 200, , RESEARCH TRIANGLE PARK, NC, 27709.

Insiders trading at Kadmon Inc

Over the last 8 years, insiders at Kadmon Inc have traded over $7,020,661 worth of Kadmon Inc stock and bought 7,084,916 units worth $54,943,934 . The most active insiders traders include Advisors Llcperceptive Life..., Asset Management Lp Golden ..., and Daniel S Third Point Llc Loeb. On average, Kadmon Inc executives and independent directors trade stock every 29 days with the average trade being worth of $1,948,175. The most recent stock trade was executed by Harlan Waksal on 13 March 2020, trading 16,000 units of KDMN stock currently worth $46,880.

What does Kadmon Inc do?

Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.

Complete history of Cynthia Flowers stock trades at Caladrius Biosciences Inc, G1 Therapeutics Inc, and Kadmon Inc

Kadmon Inc executives and stock owners

Kadmon Inc executives and other stock owners filed with the SEC include:

• Harlan Waksal,
  President, Chief Executive Officer, Director
• Steven Meehan,
  Chief Financial Officer, Executive Vice President
• Gregory Moss,
  Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
• Dr. Harlan W. Waksal,
  Pres, CEO & Director
• Gregory S. Moss Esq.,
  Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
• Arthur Kirsch,
  Independent Director
• David Cohen,
  Independent Director
• Cynthia Schwalm,
  Independent Director
• Eugene Bauer,
  Independent Director
• Tasos Konidaris,
  Non-Executive Independent Chairman of the Board
• Ellen Cavaleri,
  IR Contact Officer
• Nancy Miller-Rich,
  Director
• John Ryan,
  Executive Vice President, Chief Medical Officer
• Dr. Simon Cooper,
  Sr. VP & Chief Medical Officer
• Haya Taitel M.S., R.Ph.,
  Sr. VP & Chief Commercial Officer
• Sanjay Aggarwal,
  Sr. VP of Clinical Devel.
• Kyle Carver,
  Sr. VP, Chief Accounting Officer & Controller
• Charles Darder,
  Principle Accounting Officer
• Asset Management Lp Golden ...,
  
• D. Dixon Boardman,
  
• Konstantin Poukalov,
  EVP, Chief Financial Officer
• Alexandria Forbes,
  
• Andrew B Cohen,
  
• I, Llc Kadmon,
  
• Susan Wiviott,
  
• Shengda Zan,
  
• Thomas E Shenk,
  
• Steven N. Gordon,
  Exec VP, GC, Chief Admin, Comp
• Lawrence Kenneth Cohen,
  Exec. VP, Business Develop.
• Daniel S Third Point Llc Loeb,
  
• Bart M Schwartz,
  
• Advisors Llcperceptive Life...,
  
• Kyle Carver,
  SVP, CAO, Controller
• Cynthia Louise Flowers,
  Director